Concord Biotech: Business Overview & Financial Analysis
Concord Biotech is an R&D-driven Indian biopharmaceutical company headquartered in Ahmedabad, Gujarat. Promoted by Sudhir Vaid and supported by Rakesh Jhunjhunwala's RARE Enterprises, the company is a global leader in fermentation-based active pharmaceutical ingredients (APIs), active enzyme synthesis, and niche finished dosage formulations (FDF). Concord Biotech operates complex fermentation synthesis reactors across its manufacturing plants in Gujarat, supplying specialized immunosuppressant, oncology, anti-infective, and antifungal products to global pharmaceutical innovator and generic accounts across more than 70 countries.
Business Segment Revenue Breakdown of Concord Biotech (FY2026)
Concord Biotech categorises its operational turnover across generic active pharmaceutical ingredients (APIs) and finished dosage formulations (FDF).
- Active Pharmaceutical Ingredients (API) Segment – 85.0% of Total Revenue
- Finished Dosage Formulations (FDF) Segment – 15.0% of Total Revenue
- Total Consolidated Revenue from Operations (FY2026) – Rs 1,120.50 crore (+18.5% YoY)
The active pharmaceutical ingredient (API) vertical serves as the core revenue anchor, leveraging high-barrier microbial fermentation technology. The finished dosage formulation (FDF) division delivers higher gross margins through oral solids and liquid injectables distributed across domestic and international markets.
Therapeutic Segment Revenue Mix of Concord Biotech (FY2026)
Concord Biotech structures its product portfolio around niche, high-value fermentation-based therapeutic segments.
- Immunosuppressant Therapy Segment – 48.5% of Total Operating Revenue
- Anti-Infective & Antifungal Therapy Segment – 28.2% of Total Operating Revenue
- Oncology & Specialty Therapy Segment – 15.3% of Total Operating Revenue
- Enzymes & Other Niche Molecules – 8.0% of Total Operating Revenue
Immunosuppressants represent the primary top-line and margin driver, supplying critical post-transplant anti-rejection active ingredients to global pharmaceutical clients. Anti-infective and antifungal lines provide volume stability, while oncology molecules expand product realisations in regulated markets.
Global Market Leadership & Product Share of Concord Biotech (FY2026)
Concord Biotech commands global market share leadership across key fermentation-based API molecules.
- Global Immunosuppressant API Market Share – >20.0% Global Market Leadership Position
- Key Commercialized API Molecules Base – 23+ niche fermentation-based APIs
- Regulatory Drug Master Files (DMF) Base – 130+ global DMF filings
- Key Molecules Portfolio – Tacrolimus, Cyclosporine, Mycophenolate Mofetil, Sirolimus, and Anidulafungin
The company holds a dominant global supply position in Tacrolimus and Mycophenolate Mofetil, serving top generic drug manufacturers globally. Over 130 regulatory Drug Master Files (DMFs) support long-term supply agreements with global pharmaceutical innovators.
Geographic Revenue Mix & Export Distribution Share of Concord Biotech (FY2026)
Concord Biotech exports active pharmaceutical ingredients and formulations across major global regulated and emerging markets.
- International Exports Channel Share – 52.0% of Total Operating Revenue
- Domestic Indian Market Sales Share – 48.0% of Total Operating Revenue
- Regulated Markets Contribution Share – 42.5% of Total Revenue (USA, Europe, Japan)
- Emerging Markets & RoW Contribution Share – 9.5% of Total Revenue
- Global Export Footprint Scope – Exports to 70+ countries globally
International export dispatches generate over half of total operational turnover, led by high-margin API supplies to North American and European pharmaceutical companies. Domestic dispatches supply leading Indian formulation exporters and hospital procurement channels.
Manufacturing Facilities & Fermentation Capacity Scale of Concord Biotech (FY2026)
Concord Biotech operates vertically integrated manufacturing campuses equipped with large-scale microbial fermentation reactors.
- Operational Manufacturing Facilities Base – 3 manufacturing plants in Gujarat
- Primary Manufacturing Hub Locations – Dholka (API Unit I), Limbasi (API Unit II), and Valthera (Injectable & FDF Unit III)
- Total Installed Fermentation Reactor Capacity – 2,600+ Cubic Meters (m³)
- Global Regulatory Compliance Approvals – USFDA, EU-GMP, Japanese PMDA, and WHO-GMP certified facilities
- USFDA Audit Status – All 3 manufacturing facilities successfully inspected with zero critical observations
The Limbasi complex operates as one of India's largest fermentation-based API manufacturing sites with automated bioprocess controls. The Valthera plant manufactures complex oral solids and liquid injectables under stringent USFDA and EU-GMP compliance standards.
Latest Quarterly Financial Performance of Concord Biotech (Q1 FY2027)
Concord Biotech recorded top-line revenue expansion and operating profit growth during the first quarter of FY2027.
- Consolidated Revenue from Operations – Rs 285.40 crore (+16.2% YoY)
- Consolidated Operating EBITDA – Rs 118.20 crore (+18.5% YoY)
- Operating EBITDA Margin – 41.41% (+82 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 82.40 crore (+21.4% YoY)
- Board Recommended Interim Dividend – Disclosed as per annual capital allocation policy
First-quarter operating revenue rose 16.2% year-on-year to Rs 285.40 crore, supported by volume growth in immunosuppressant API exports. Consolidated Net Profit After Tax reached Rs 82.40 crore, while operating EBITDA margins expanded to 41.41% due to product mix enrichment.
Consolidated Annual Financial Performance of Concord Biotech (FY2026)
Concord Biotech delivered full-year turnover expansion and record net profitability for full financial year FY2026.
- Full Year Consolidated Revenue from Operations – Rs 1,120.50 crore (+18.5% YoY)
- Full Year Consolidated Operating EBITDA – Rs 462.50 crore (+21.2% YoY)
- Full Year Operating EBITDA Margin – 41.28% (+92 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 318.20 crore (+24.5% YoY)
- Return on Capital Employed (ROCE) – 26.8%
Full-year operating turnover crossed Rs 1,120 crore in FY2026, as consolidated Net Profit After Tax expanded 24.5% to Rs 318.20 crore. Financial performance was supported by capacity expansion at Limbasi, high operating leverage, and stable raw material input costs.
Balance Sheet Structure & Financial Health Ratios of Concord Biotech (Q1 FY2027)
Concord Biotech operates a zero-debt financial model supported by strong operating cash generation and surplus cash reserves.
- Debt to Equity Ratio – Net Cash Positive / Zero Debt (0.00x)
- Total Cash, Bank Balances & Surplus Investments – Rs 850.00 crore
- Total Consolidated Net Worth Base – Rs 1,850.00 crore
- Return on Equity (ROE) – 21.5%
- Working Capital Cycle – 112 days
The company closed Q1 FY2027 with zero long-term financial debt and Rs 850.00 crore in liquid surplus reserves. High capital efficiency generated a Return on Capital Employed of 26.8%, funding internal facility expansions without debt reliance.
Capital Expenditure & Injectables Expansion Roadmap of Concord Biotech (FY2027–FY2028)
Concord Biotech executes capital allocation outlays to expand injectable formulation lines and debottleneck fermentation capacity.
- Planned Annual Capital Expenditure – Rs 150–200 crore per annum over FY2027–FY2028
- Valthera Injectables Plant Expansion – Scaling complex oncology and anti-infective liquid/lyophilized vial lines
- Limbasi Fermentation Capacity Outlay – Adding 400+ m³ fermentation capacity for anti-infective APIs
- R&D Innovation & Bioprocess Outlay – Developing high-potency fermentation molecules and enzyme catalysts
- Funding Method – 100% funded through internal operational cash accruals and liquid reserves
Annual capital expenditure is budgeted at Rs 150–200 crore over FY2027–FY2028 to expand injectable formulation lines at Valthera and fermentation capacity at Limbasi. Internal cash flows fund all planned facility modernizations without external borrowing.
Strategic Outlook & Management Commentary of Concord Biotech (Q1 FY2027 Concall)
Management guidance outlines strategic priorities centered on immunosuppressant market share expansion, formulation commercialization, and margin protection.
- Management targets achieving a 18%–20% top-line revenue CAGR over the FY2027–FY2029 period.
- Operating EBITDA margins are guided to sustain within the 40.0%–42.5% corridor through high-margin product mix execution.
- Finished Dosage Formulation (FDF) share in overall sales is targeted to expand toward 20% over the next 3 years.
- Injectable product filings will be scaled across USFDA and European regulatory agencies to drive hospital supply contracts.
- Capital allocation strategy will prioritize funding internal brownfield expansions while maintaining a debt-free balance sheet.
Management anticipates global demand for immunosuppressant APIs and fermentation-based niche molecules to support volume execution. Operational focus centers on commercializing new injectable formulations, ramping up Limbasi capacity utilization, and preserving balance sheet strength.
Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.
Sources & References
- Concord Biotech Q1 FY2027 Consolidated Financial Disclosures (July/August 2026)
- Concord Biotech Q4 & Full Year FY2026 Consolidated Financial Results Disclosures (May 2026)
- BSE India & National Stock Exchange of India (NSE) Corporate Filings for Concord Biotech
- Ticker Finology Concord Biotech Page
Disclaimer
The information presented above on Concord Biotech has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Concord Biotech page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.